Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Director's Dealing 2022

Feb 16, 2022

29750_dirs_2022-02-15_ba2c7f52-42ec-41a1-8a0f-e9d7934f29aa.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2022-02-14

Reporting Person: McEvoy Ashley (EVP, WW Chair, Medical Devices)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-14 Common Stock M 2885.0000 $0.0000 Acquired 33040.9545 Direct
2022-02-14 Common Stock F 792.0000 $168.8500 Disposed 32248.9545 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-14 Restricted Share Units $ M 2885.0000 Disposed Common Stock (2885.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2607.0000 Indirect
Common Stock 300.0000 Indirect

Footnotes

F1: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.

F2: Shares withheld for payment of taxes upon vesting of Restricted Share Units.

F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2022).

F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2022).